LONG-TERM SAFETY AND EFFICACY OF IVACAFTOR IN PATIENTS WITH CYSTIC FIBROSIS WHO HAVE THEG551D-CFTRMUTATION: RESPONSE THROUGH 144 WEEKS OF TREATMENT (96 WEEKS OF PERSIST)

1. St. Vincent's University Hospital, Dublin, Ireland; 2. State University of New York at Buffalo, Buffalo, NY, USA; 3. 2nd Medical School, Charles University, Prague, Czech Republic; 4. Childrens' Hospital, University of Munich, Munich, Germany; 5. Case Western Reserve University School of Medicine Rainbow Babies and Children's Hospital, Cleveland, OH, USA; 6. Royal Children's Hospital Brisbane, Herston, QLD, Australia; 7. The Hospital for Sick Children, Toronto, ON, Canada; 8. Centre d'Investigation Clinique - Hopital Necker, Paris, France; 9. Cork University Hospital, Cork, Ireland; 10. Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 11. Royal Brompton Hospital, London, United Kingdom